Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

llaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updati
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013   Oligomerix, Inc. ... of disease modifying therapeutics for Alzheimer,s disease (AD) ... of its Series B financing, which includes both ... that would represent approximately $2.8M in new investments ... investors supported the raise. Funding ...
(Date:5/22/2013)... 2013 Genedata, a leading provider ... discovery, and life science research, today announced AB ... as its bioinformatics platform for strain genome data ... provide AB Enzymes, one of the world’s oldest ... of Genedata Selector accompanied by bioinformatics consulting services. ...
(Date:5/22/2013)... MN (PRWEB) May 22, 2013 ... Medical Supplies Pty Ltd are pleased to announce ... is the Australian and New Zealand distributor of DrugCheck® ... V8 Supercar Team participated in the Austin 400 May ... entered into an agreement that involves each car of ...
(Date:5/22/2013)... The ability to sequence genomes has ... encode. There are now a suite of applications ... protected fragments) that dramatically expand our ability to ... Dr. Jonathan Weissman, an Investigator with the University ... Institute, who will present recent applications of their ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2
... 3 Varian, Inc.,(NasdaqGS: VARI) announced today ... detectors (ELSD) for conventional and high speed ... and solvent,compatibility, and excellent baseline stability, Varian ... RI detectors for busy pharmaceutical,and analytical laboratories. ...
... Amarin Corporation plc,(NASDAQ: AMRN ) today ... license with,Scarista Limited ("Scarista") for the development ... portfolio in the field of lipid,science. This ... lipid-based development programs including AMR101 and its ...
... Spiral lead offers flexibility for placement in small, medium and ... ... March 3 Boston Scientific,Corporation (NYSE: BSX ) today announced ... with cardiac resynchronization therapy,defibrillators and cardiac resynchronization therapy pacemakers, both of,which ...
Cached Biology Technology:New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3Amarin Secures Global Intellectual Property Rights for Lipid Programs 4Boston Scientific Announces European Approval of New Heart Failure Lead 2Boston Scientific Announces European Approval of New Heart Failure Lead 3
(Date:5/22/2013)... Early screening for prostate cancer could become as easy ... thanks to UC Irvine research published today in the ... After more than a decade of work, UC Irvine ... usable markers for prostate cancer in urine, meaning that ... accuracy and at dramatically lower cost. The same technology ...
(Date:5/21/2013)... concept of "place" is increasingly being considered in ... have a new resource that can help them ... with the places in their lives. , ... new book co-edited by the Pacific Northwest Research ... human-centered approach to conservation. The book is published ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3MU researchers develop radioactive nanoparticles that target cancer cells 2
... Rochelle, NY, May 20, 2009Small synthetic fragments of genetic ... of abnormal proteins; however, these exciting new drug candidates ... side effects. Understanding how siRNA stimulates this undesirable immune ... design siRNA drugs to avoid it are critical topics ...
... “New Strategies for Optimizing CHO Performance,” to feature ... ZAP-CHO during BIO 2009 International Convention in Atlanta, ... / b3c newswire / – InVitria’s Director ... the performance enhancing features of ZAP-CHO, a new ...
... Barron and his group, working with labs in Italy, Germany ... means by which the deadly virus spreads by taking away ... computer simulations, researchers tested more than 100 carbon fullerene, or ... see if they could be used to inhibit a strain ...
Cached Biology News:Strong immune response to new siRNA drugs in development may cause toxic side effects 2InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO 2International team tracks clues to HIV 2International team tracks clues to HIV 3
Recombinant Human HGF...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
... to histochemically detect specific ... pH in cultured cells ... specific marker is only ... (not found in presenescent/quiescent/immortal ...
Recombinant Mouse LIGHT/TNFSF14...
Biology Products: